Open AccessKRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
Author(s) -
Juan Esteban García-Robledo,
Rafael Rosell,
Alejandro Ruíz-Patiño,
Carolina Sotelo,
Óscar Arrieta,
Lucía Zatarain-Barrón,
Camila Ordoñez,
Elvira Jaller,
Leonardo Rojas,
Alessandro Russo,
Diego Pérez,
Christian Rolfo,
Andrés F. Cardona
Publication year - 2022
Publication title -
therapeutic advances in respiratory disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.022
H-Index - 37
eISSN - 1753-4666
pISSN - 1753-4658
DOI - 10.1177/17534666211066064
Subject(s) - kras , medicine , lung cancer , carcinogenesis , cancer , disease , targeted therapy , genomics , cancer research , bioinformatics , oncology , colorectal cancer , gene , biology , genetics , genome
Non-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor’s molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.